Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 5:2022:3881962.
doi: 10.1155/2022/3881962. eCollection 2022.

Effects on Autophagy of Moxibustion at Governor Vessel Acupoints in APP/PS1double-Transgenic Alzheimer's Disease Mice through the lncRNA Six3os1/miR-511-3p/AKT3 Molecular Axis

Affiliations

Effects on Autophagy of Moxibustion at Governor Vessel Acupoints in APP/PS1double-Transgenic Alzheimer's Disease Mice through the lncRNA Six3os1/miR-511-3p/AKT3 Molecular Axis

Yu-Mei Jia et al. Evid Based Complement Alternat Med. .

Abstract

Objective: To explore the effect and mechanism of moxibustion at acupoints of the governor vessel on lncRNA Six3os1 in amyloid precursor protein/presenilin1 (APP/PS1) double-transgenic Alzheimer's disease (AD) mice.

Methods: Twenty-four specific pathogen-free and APP/PS1 double-transgenic male mice were randomly allocated into the AD model and moxibustion groups, with 12 cases in each group. Twelve syngeneic C57BL/6J mice were selected as the control group. Mice in the moxibustion group received aconite cake-separated moxibustion at the Baihui acupoint. Suspension moxibustion was applied at Fengfu and Dazhui for 15 minutes each day. All treatments were conducted over two weeks. Control and AD model mice were routinely fed without any intervention. Behavioral observation tests were conducted before and after the intervention. The autophagosome in the hippocampus was observed using transmission electron microscopy. Immunohistochemistry was performed to detect Aβ1-42 expression. LC3B and P62 expressions were evaluated by immunofluorescence. The expression levels of the lncRNAs Six3os1, miR-511-3p, and AKT3 were detected by qRT-PCR. The differential expression of PI-3K, AKT3, mTOR, LC3B-II/I, and P62 proteins in the hippocampus was detected by western blot. The dual-luciferase assay was undertaken to examine the targeting relationships of the lncRNAs Six3os1, miR-511-3p, and AKT3.

Results: Compared with the control group, the AD model showed higher escape latency in the Morris Water Maze and reduced autophagic vacuoles in the cytoplasm of hippocampal neurons (both p < 0.01). Compared with the control group, the AD model showed higher expression of Aβ1-42, the lncRNAs Six3os1, PI-3K, mTOR, P62, and AKT3 protein (all p < 0.01); but lower mir-511-3p and LC3B (both p < 0.01). Compared with the AD model group, the moxibustion group had a shorter escape latency, more autophagic bubbles in the hippocampus, and lower expression of positive Aβ1-42, the lncRNAs Six3os1, PI-3K, mTOR, P62, and AKT3 protein (all p < 0.01). In contrast, the levels of miR-511-3p and LC3B proteins were considerably increased in the moxibustion group compared to the AD model group (both p < 0.01). Based on the dual-luciferase assay, there was a targeting link among the lncRNAs Six3os1, miR-511-3p, and AKT3.

Conclusion: Moxibustion at acupoints of the governor vessel can suppress the lncRNA Six3os1 expression, promote cell autophagy, accelerate Aβ1-42 clearance and alleviate cognitive dysfunction of AD mediated by the PI3K/AKT/mTOR signaling pathway through the lncRNA Six3os1/miR-511-3p/AKT3 axis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Comparison of Morris Water Maze escapes latency (mean ± SD, n = 12). Note: ∗∗indicates significant difference versus the control group, at p < 0.01; ##indicates significant difference versus the AD model group, at p < 0.01.
Figure 2
Figure 2
Cytoplasmic ultrastructural structures in the hippocampus. Note: the red arrow indicates autophagic vacuoles; the yellow arrow indicates autophagosome.
Figure 3
Figure 3
Hippocampal Aβ1–42 protein content (mean ± SD, n = 3). Note: arrows indicate senile plaques. ∗∗indicates significant difference versus the control group, at p < 0.01; ##indicates significant difference versus the AD model group, at p < 0.01.
Figure 4
Figure 4
Expression of the lncRNAs Six3os1, miR-511-3p, and AKT3 in the hippocampus (mean ± SD, n = 6). Note: ∗∗indicates significant difference versus the control group, at p < 0.01; ##indicates significant difference versus the AD model group, at p < 0.01.
Figure 5
Figure 5
LC3B-II/I ratio and P62 hippocampal expression (mean ± SD, n = 6). Note: ∗∗indicates significant difference versus the control group, at p < 0.01; ##indicates significant difference versus the AD model group, at p < 0.01.
Figure 6
Figure 6
Hippocampal expression of LC3B and P62 (mean ± SD, n = 3). Note: Nuclei are in blue and LC3B/P62 are in green. (a) LC3B average optical density; (b) P62 average optical density. ∗∗indicates significant difference versus the control group, at p < 0.01; ##indicates significant difference versus the AD model group, at p < 0.01.
Figure 7
Figure 7
Hippocampal expression of PI3K, AKT3, and mTOR proteins (mean ± SD, n = 6). Note: ∗∗indicates significant difference versus the control group, at p < 0.01; ##indicates significant difference versus the AD model group, at p < 0.01.
Figure 8
Figure 8
Schematic diagram of the predicted binding site: (a) Schematic diagram of hsa-miR-511-3p binding to lncRNA-Six3os1 target sites; (b) schematic diagram of hsa-miR-511-3p binding to AKT target sites.
Figure 9
Figure 9
Dual-luciferase activity analysis. Group 1. NC mimics + hsa-lncRNA-Six3os1-3UTR-wt; Group 2. has-miR-511-3p + hsa-lncRNA-Six3os1-3UTR-wt; Group 3. NC mimics + has-lncRNA-Six3os1-3UTR-mut; Group 4. has-miR-511-3p + hsa-lncRNA-Six3os1-3UTR-mut (∗∗indicates a statistically significant difference at p < 0.01).
Figure 10
Figure 10
Dual-luciferase activity analysis. Group 1. NC mimics + hsa-AKT-3UTR-wt; Group 2. has-miR-511-3p + hsa-AKT-3UTR-wt; Group 3. NC mimics + has-AKT-3UTR-mut; Group 4. has-miR-511-3p + hsa-AKT-3UTR-mut. (∗∗indicates a statistically significant difference at p < 0.01).

Similar articles

Cited by

References

    1. Zhang X. X., Tian Y., Wang Z. T., Ma Y. H., Tan L., Yu J. T. The epidemiology of Alzheimer’s disease modifiable risk factors and prevention. Journal of Prevention of Alzheimer’ Disease . 2021;8(3):313–321. doi: 10.14283/jpad.2021.15. - DOI - PubMed
    1. Yang P., Sun F. Aducanumab: the first targeted Alzheimer’s therapy. Drug Discoveries & Therapeutics . 2021;15(3) doi: 10.5582/ddt.2021.01061. - DOI - PubMed
    1. Lozupone M., Solfrizzi V., D’Urso F., et al. Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs. Expert Opinion on Emerging Drugs . 2020;25(3):319–335. doi: 10.1080/14728214.2020.1808621. - DOI - PubMed
    1. Tolar M., Abushakra S., Sabbagh M. The path forward in Alzheimer’s disease therapeutics: reevaluating the amyloid cascade hypothesis. Alzheimer’s and Dementia . 2020;16(11):1553–1560. doi: 10.1016/j.jalz.2019.09.075. - DOI - PubMed
    1. Athar T., Al Balushi K., Khan S. A. Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease. Molecular Biology Reports . 2021;48(7):5629–5645. doi: 10.1007/s11033-021-06512-9. - DOI - PMC - PubMed